Publication

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease

Downloadable Content

Persistent URL
Last modified
  • 05/21/2025
Type of Material
Authors
    Anurag Mehta, Emory UniversityShivang R. Desai, Emory UniversityYi-An Ko, Emory UniversityChang Liu, Emory UniversityDevinder S. Dhindsa, Emory UniversityAditi Nayak, Emory UniversityAnanya Hooda, Emory UniversityMohamed A. Martini, Emory UniversityKiran Ejaz, Emory UniversityLaurence Sperling, Emory UniversityJochen Reiser, Rush UniversitySalim S. Hayek, University of MichiganArshed Quyyumi, Emory University
Language
  • English
Date
  • 2020-03-03
Publisher
  • Wiley
Publication Version
Copyright Statement
  • © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 9
Issue
  • 5
Grant/Funding Information
  • Mehta is supported by American Heart Association grant 19POST34400057 and Abraham J. & Phyllis Katz Foundation. Quyyumi is supported by NIH grants 1P20HL113451‐01, 1R61HL138657‐02, 1P30DK111024‐03S1, 5R01HL095479‐08, 3RF1AG051633‐01S2, 5R01AG042127‐06, 2P01HL086773‐08, U54AG062334‐01, 1R01HL141205‐01, 5P01HL101398‐02, 1P20HL113451‐01, 5P01HL086773‐09, 1RF1AG051633‐01, R01 NS064162‐01, R01 HL89650‐01, HL095479‐01, 1DP3DK094346‐01, 2P01HL086773, and American Heart Association grant 15SFCRN23910003.
Supplemental Material (URL)
Abstract
  • Background Women have higher circulating levels of soluble urokinase‐type plasminogen activator receptor (suPAR), and elevated suPAR is associated with cardiovascular risk. The independent association of sex with suPAR and the impact of sex on its association with cardiovascular risk are unknown. Methods and Results Plasma suPAR was measured using ELISA in 2 cohorts of 666 asymptomatic individuals (49 years, 65% women) and 4184 patients with coronary artery disease (63 years, 37% women). Independent association of sex with suPAR was studied using linear regression models adjusted for demographics, risk factors, and visceral adiposity in asymptomatic participants. Impact of sex on association of suPAR with all‐cause mortality was studied in patients with coronary artery disease using multivariable‐adjusted Cox models. Sex‐specific suPAR cutoffs for predicting all‐cause mortality were calculated. Asymptomatic women had 10% higher suPAR compared with men after adjusting for confounders, and visceral adiposity partly accounted for this association. Over a median follow‐up of 5.2 years, 795 deaths were recorded in patients with coronary artery disease. Log2‐transformed suPAR was independently associated with mortality (hazard ratio per 1‐SD 1.72, 95% CI 1.60–1.85) and an interaction with sex was noted (P=0.005). Association of suPAR with mortality was slightly weaker in women (hazard ratio 1.61, 95% CI 1.41–1.83) compared with men (hazard ratio 1.83, 95% CI 1.67–2.00). However, using sex‐specific suPAR cut‐offs (4392 pg/mL for women and 3187 pg/mL for men), a similar mortality incidence was observed for both sexes (38.5% and 35.5%, respectively, P=0.3). Conclusions Women have 10% higher plasma suPAR levels compared with men. Elevated sex‐specific plasma suPAR levels are equally predictive of risk of adverse events in both sexes.
Author Notes
  • Arshed A. Quyyumi, MD, Bruce Logue Chair for Cardiovascular Research, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, 1462 Clifton Rd Northeast, Suite 507, Atlanta, GA 30322. E‐mail: aquyyum@emory.edu
Keywords
Research Categories
  • Gender Studies
  • Biology, Cell

Tools

Relations

In Collection:

Items